» Articles » PMID: 38448808

Tropheryma Whipplei Infection in the Lung of a Patient with Long COVID: a Case Report

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2024 Mar 6
PMID 38448808
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immune dysregulation in individuals with long COVID has been detected. Differential diagnosis of diffuse infiltration on chest CT in long COVID is challenging.

Case Presentation: A 62-year-old man presented with a 10-month history of dyspnea after COVID-19 infection. Dyspnea became worse in the one month preceding presentation. The chest CT showed multifocal, subpleural, bilateral opacities due to long-COVID, and infiltration around the bronchovascular bundle in the bilateral lower lung field. The pathology for the transbronchial cryobiopsy (TBCB) first reported chronic inflammation (mainly interstitial pneumonia). The patient had positive results on tests for the antibody, RO-52+, EJ+. The presumptive diagnosis of connective tissue disease-interstitial lung disease was made. Prednisone and cyclophosphamide were given. At follow-up one month later, the chest CT showed new diffuse ground-glass infiltration. The previous TBCB specimen was re-evaluated. Foamy macrophages were found in the alveolar air space. Periodic acid-Schiff (PAS) staining was performed. Numerous intracytoplasmic organisms were detected, with morphologic features consistent with those of Tropheryma whipplei. The patient recovered after intravenous ceftriaxone and oral trimethoprim-sulfamethoxazole. The final diagnosis was lung T. whipplei infection and long COVID-19.

Conclusion: This is the first case report of Tropheryma whipplei infection in the lung of a patient with long COVID-19. T. whipplei should be considered as a potential pathogen for diffuse lung infiltration in the post-COVID-19 era.

Citing Articles

Short-Term Amoxicillin Clavulanate in the Treatment of Pulmonary Abscess Caused by Infection Diagnosed by Targeted Next-Generation Sequencing: A Case Report and Literature Review.

Zhou H, Zhang J Infect Drug Resist. 2024; 17:4607-4616.

PMID: 39464838 PMC: 11512776. DOI: 10.2147/IDR.S488740.

References
1.
Wu S, Tang X, Wu L, Lu L, Feng X . Anti-Ro52 antibodies in clinical practice: A single-centre experience. Int J Clin Pract. 2020; 75(3):e13679. DOI: 10.1111/ijcp.13679. View

2.
Gangneux J, Dannaoui E, Fekkar A, Luyt C, Botterel F, de Prost N . Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021; 10(2):180-190. PMC: 8626095. DOI: 10.1016/S2213-2600(21)00442-2. View

3.
Winberg C, Rose M, Rappaport H . Whipple's disease of the lung. Am J Med. 1978; 65(5):873-80. DOI: 10.1016/0002-9343(78)90809-4. View

4.
Durand D, Lecomte C, Cathebras P, Rousset H, Godeau P . Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne. Medicine (Baltimore). 1997; 76(3):170-84. DOI: 10.1097/00005792-199705000-00003. View

5.
Shim D, Kim H, Shin S . Infection-Driven Foamy Macrophages and Their Implications in Tuberculosis Control as Targets for Host-Directed Therapy. Front Immunol. 2020; 11:910. PMC: 7235167. DOI: 10.3389/fimmu.2020.00910. View